This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT)

This study has been completed.
Sponsor:
Collaborator:
University of Rochester
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00180271
First received: September 9, 2005
Last updated: January 24, 2012
Last verified: January 2012
Results First Received: February 23, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Tachycardia
Congestive Heart Failure
Interventions: Device: Cardiac resynchronization therapy with defibrillation
Device: Implantable Cardioverter Defibrillator (ICD)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study enrolled 1820 patients from 110 hospital centers (88 in the United States, 2 in Canada, and 20 in Europe) between December 22, 2004 and April 23, 2008. Follow-up continued thereafter until trial termination.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Data from all patients enrolled were analyzed on an intention-to-treat basis.

Reporting Groups
  Description
Cardiac Resynchronization Therapy + Defibrillator Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.
Implantable Cardioverter Defibrillator Alone Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.

Participant Flow:   Overall Study
    Cardiac Resynchronization Therapy + Defibrillator   Implantable Cardioverter Defibrillator Alone
STARTED   1089   731 
COMPLETED   1089   731 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cardiac Resynchronization Therapy + Defibrillator Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.
Implantable Cardioverter Defibrillator Alone Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.
Total Total of all reporting groups

Baseline Measures
   Cardiac Resynchronization Therapy + Defibrillator   Implantable Cardioverter Defibrillator Alone   Total 
Overall Participants Analyzed 
[Units: Participants]
 1089   731   1820 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   543   380   923 
>=65 years   546   351   897 
Age 
[Units: Years]
Mean (Standard Deviation)
 65  (11)   64  (11)   65  (11) 
Gender 
[Units: Participants]
     
Female   275   178   453 
Male   814   553   1367 
Region of Enrollment 
[Units: Participants]
     
United States   757   514   1271 
Canada   14   8   22 
Czech Republic   17   11   28 
Denmark   22   13   35 
France   13   9   22 
Germany   98   61   159 
Hungary   16   10   26 
Israel   45   30   75 
Italy   15   12   27 
Netherlands   34   24   58 
Poland   14   10   24 
Spain   36   24   60 
Switzerland   4   2   6 
United Kingdom   4   3   7 


  Outcome Measures

1.  Primary:   Mortality From Any Cause or First Heart Failure (HF) Event   [ Time Frame: Outcome measured at average follow-up duration of 2.4 years. ]

2.  Secondary:   Recurrent Heart Failure Events   [ Time Frame: Time of event, DSMB review ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The FDA Circulatory Devices advisory panel recommended approval for the patient subpopulation with left bundle branch block (LBBB) only. Consequently, FDA has restricted indications for use to LBBB.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Lisa Melchior
Organization: Boston Scientific
phone: 800 227 3422
e-mail: lisa.melchior@bsci.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT00180271     History of Changes
Other Study ID Numbers: Clinicals0003
MADIT-CRT
Study First Received: September 9, 2005
Results First Received: February 23, 2011
Last Updated: January 24, 2012